tiprankstipranks
Allergy Therapeutics Shows Financial Turnaround and Clinical Progress
Company Announcements

Allergy Therapeutics Shows Financial Turnaround and Clinical Progress

Allergy Therapeutics (GB:AGY) has released an update.

Don't Miss Our Christmas Offers:

Allergy Therapeutics has shown promising financial recovery with its first half-year revenue growth since 2021, despite overall annual revenue decline due to supply constraints. The company reported a 36% reduction in EBITDA losses and strengthened its cash position through a new funding facility. Key clinical trials, including the Grass MATA MPL and VLP Peanut PROTECT, are progressing well, enhancing the company’s strategic outlook.

For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskAllergy Therapeutics Rectifies Share Option Oversight
TipRanks UK Auto-Generated NewsdeskAllergy Therapeutics Shows Promising Results for Peanut Allergy
TipRanks UK Auto-Generated NewsdeskAllergy Therapeutics Begins Innovative Paediatric Allergy Trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App